New hope for lymphoma patients as trial tests pill to control resistant cancer
NCT ID NCT06716658
Summary
This study is testing an oral medication called golidocitnib for people with slow-growing T/NK-cell lymphomas that have come back or haven't responded to prior treatments. The goal is to see if this once-daily pill can effectively shrink tumors and control the disease. Researchers will enroll 48 patients to measure how well the drug works and monitor its safety over up to two years of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
NOT_YET_RECRUITINGTianjin, 300020, China
-
Institute of Hematology & Blood Diseases Hospital, China
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.